Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI) (EPHICACI)
Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections
EPHICACI is a multicenter, prospective study that continues and expands the monocentric PHAGEFORCE registry initiated at UZ Leuven. In Belgium, phage therapy can be applied as standard-of-care only in patients with difficult-to-treat infections where no curative antibiotic and/or surgical alternatives are available ('last-resort cases'). A multidisciplinary phage task force, the Coordination group for Bacteriophage therapy Leuven (CBL), evaluates eligible patients, tests pathogen susceptibility, and sets up standardized treatment protocols. With EPHICACI, this approach is extended to multiple Belgian expert centers to increase patient enrollment while upholding stringent eligibility criteria. The study aims to gain insight into the safety, efficacy, biodistribution and mechanisms of action of phage therapy, and to optimize its use across five medical disciplines (with distinct routes of administration). In addition, EPHICACI integrates machine learning-based phage-bacteria interaction analyses to guide personalized phage selection, and includes health economic evaluations to support evidence-based implementation and reimbursement strategies.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Patients with difficult-to-treat musculoskeletal infections, chronic rhinosinusitis, persistent bacteremia, pulmonary infections associated with cystic fibrosis or bronchiectasis, or hidradenitis suppurativa, for whom no standard (curative) treatment options are available, are eligible for phage therapy. Patient eligibility is assessed by the multidisciplinary Coordination group for Bacteriophage therapy Leuven (CBL), in collaboration with multiple Belgian expert centers. If phages with activity against the isolated bacterial strain are identified and the patient meets all inclusion criteria, a phagogram is performed. Based on these results, patients are either assigned to receive phage therapy or remain in the control group receiving best available non-curative treatment. In both groups, standardized clinical, microbiological and health economic data are collected prospectively using REDCap.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Jolien Onsea, PhD
- Número de telefone: 00321642041
- E-mail: jolien.onsea@uzleuven.be
Estude backup de contato
- Nome: Willem-Jan Metsemakers, MD, PhD
- Número de telefone: 003216344277
- E-mail: willem-jan.metsemakers@uzleuven.be
Locais de estudo
-
-
-
Leuven, Bélgica, 3000
- Recrutamento
- University Hospitals Leuven
-
Contato:
- Willem-Jan Metsemakers, MD, PhD
- Número de telefone: 003216344277
- E-mail: willem-jan.metsemakers@uzleuven.be
-
Contato:
- Jolien Onsea, PhD
- Número de telefone: 003216342041
- E-mail: jolien.onsea@uzleuven.be
-
Investigador principal:
- Willem-Jan Metsemakers, MD, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
All patients:
- Diagnosed with an MSI or CRS or persistent bacteremia or or pulmonary infection (cystic fibrosis/bronchiectasis) or HS and
- For whom all previous treatments (surgical and antibiotic) have failed or for whom no other treatment options are available (i.e., last resort cases, based on the assessment of the local phage hub), for example in case of bacterial resistance. And
- Of whom the pathogen causative for the infection is one for which phages are available in the phage bank, and
- Who have given informed consent to have their data collected in a patient registry.
Descrição
Inclusion criteria
- Diagnosed with an MSI or CRS or persistent bacteremia or pulmonary infection (cystic fibrosis/bronchiectasis) or HS and
- For whom all previous treatments (surgical and antibiotic) have failed or for whom no other treatment options are available (i.e., last resort cases, based on the assessment of the local phage hub), for example in case of bacterial resistance. And
- Of whom the pathogen causative for the infection is one for which phages are available in the phage bank, and
- Who have given informed consent to have their data collected in a patient registry
Exclusion Criteria:
All patients:
- With an infectious disease other than those mentioned above, and/or
- For whom standard treatment alternatives are still available. And/or
- Of whom the pathogen causative for the infection is not one for which phages are available in the phage bank. And/or
- Who refused to give their informed consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Phage treated group
Patients whose isolated pathogens are susceptible to the available phages and who have no alternative curative treatment options are included in the phage-treated group. The local phage hub, in consultation with the Phage Consortium, will design the phage therapy treatment plan (local, inhalation, or intravenous) on top of standard surgical and/or antimicrobial care. The treatment plan is documented in the patient's medical file. Patients undergo monitoring according to the phage therapy protocol and follow-up according to standard care for phage-treated patients. |
Prospective data collection prior to, during and after phage treatment. |
|
Control group
Patients whose isolated pathogens are not susceptible to available phages, or for whom phage therapy is not indicated, are included in the control group. These patients receive standard surgical and/or antimicrobial care as determined by the local phage hub. Monitoring and follow-up are according to the standard of care for the underlying pathology. |
Prospective data collection prior to, during and after standard infection treatment. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Disease-free period
Prazo: Until 1 year after treatment
|
In MSI patients |
Until 1 year after treatment
|
|
Smell test
Prazo: Until 1 year after treatment
|
16-point Sniffin' Sticks test in CRS patients |
Until 1 year after treatment
|
|
Radiological scores
Prazo: Until 1 year after treatment
|
Lund-Mackay CT score in CRS patients |
Until 1 year after treatment
|
|
Endoscopic scores
Prazo: Until 1 year after treatment
|
Lund-Kennedy score and Modified Davos score in CRS patients |
Until 1 year after treatment
|
|
Time to clearance of infection
Prazo: Until 1 year after treatment, daily during hospitalization until infection clearance
|
In patients with Persistent Bacteremia |
Until 1 year after treatment, daily during hospitalization until infection clearance
|
|
Overall survival
Prazo: Until 1 year after treatment
|
Does the patient survive (for patients with Persistent Bacteremia) |
Until 1 year after treatment
|
|
SOFA score
Prazo: Baseeline and daily during hospitalization until discharge, for up to 12 weeks after cessation of phage therapy; thereafter at 6 months and 1 year after cessation of phage therapy.
|
Sequential Organ Failure Assessment (SOFA) score in patients with persistent bacteremia, assessed to monitor changes in organ dysfunction during hospitalization. |
Baseeline and daily during hospitalization until discharge, for up to 12 weeks after cessation of phage therapy; thereafter at 6 months and 1 year after cessation of phage therapy.
|
|
Tolerance of the intervention
Prazo: During scheduled phage therapy (up to 6 weeks)
|
Proportion of patients with chronic pulmonary infection able to complete the planned phage therapy without treatment discontinuation due to adverse reactions or pulmonary exacerbations. |
During scheduled phage therapy (up to 6 weeks)
|
|
Sputum culture conversion assessed by microbiological culture
Prazo: Days 1-4 of phage therapy, weekly during phage therapy for up to 6 weeks, and at 6 and 12 months after completion of phage therapy.
|
Proportion of patients with chronic pulmonary infection with conversion from a positive sputum culture for the targeted bacterial pathogen at baseline to a negative sputum culture for the targeted bacterial pathogen after phage therapy. |
Days 1-4 of phage therapy, weekly during phage therapy for up to 6 weeks, and at 6 and 12 months after completion of phage therapy.
|
|
Within-subject change in the number of positive cultures
Prazo: At 6 and 12 months compared to 12 months prior to therapy
|
In patients with Chronic Pulmonary Infection |
At 6 and 12 months compared to 12 months prior to therapy
|
|
Within-subject change in the number of pulmonary exacerbations requiring additional antibiotic therapy or hospitalization.
Prazo: At 6 and 12 months
|
In patients with Chronic Pulmonary Infection |
At 6 and 12 months
|
|
Clinical response measured by forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC).
Prazo: Until 1 year after treatment
|
In patients with Chronic Pulmonary Infection |
Until 1 year after treatment
|
|
Improvement in IHS4 score
Prazo: Until 1 year after treatment
|
In HS patients |
Until 1 year after treatment
|
|
Improvement in ANF count using HiSCR50 and HiSCR75
Prazo: Until 1 year after treatment
|
In HS patients |
Until 1 year after treatment
|
|
Reduction in flare incidence compared to the 12 weeks prior to treatment.
Prazo: Until 1 year after treatment
|
In HS patients |
Until 1 year after treatment
|
|
Bacterial load in sinonasal material measured by quantitative microbiological culture
Prazo: Until 1 year after treatment
|
Bacterial load of the targeted bacterial pathogen in sinonasal samples from CRS patients quantified by microbiological culture and expressed as colony-forming units (CFU). |
Until 1 year after treatment
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
PROMIS global health
Prazo: until 1 year after treatment
|
specific to MSI, CRS, Chronic Pulmonary Infection |
until 1 year after treatment
|
|
PROMIS pain interference
Prazo: until 1 year after treatment
|
specific to MSI, CRS |
until 1 year after treatment
|
|
PROMIS physical function
Prazo: until 1 year after treatment
|
specific to MSI, CRS |
until 1 year after treatment
|
|
iMCQ
Prazo: until 1 year after treatment
|
specific to MSI, CRS, Persistent bacteremia |
until 1 year after treatment
|
|
iPCQ
Prazo: until 1 year after treatment
|
specific to MSI, CRS, Persistent bacteremia |
until 1 year after treatment
|
|
EQ-5D-5L
Prazo: until 1 year after treatment
|
specific to MSI, CRS, Persistent bacteremia, Chronic Pulmonary Infection, HS |
until 1 year after treatment
|
|
SNOT-22
Prazo: until 1 year after treatment
|
specific to CRS |
until 1 year after treatment
|
|
VAS pain
Prazo: until 1 year after treatment
|
specific to CRS, HS |
until 1 year after treatment
|
|
CF-Q
Prazo: until 1 year after treatment
|
specific to Chronic Pulmonary Infection |
until 1 year after treatment
|
|
Bronchiectasis QoL
Prazo: until 1 year after treatment
|
specific to Chronic Pulmonary Infection |
until 1 year after treatment
|
|
FEV1
Prazo: until 1 year after treatment
|
specific to Chronic Pulmonary Infection |
until 1 year after treatment
|
|
FVC
Prazo: until 1 year after treatment
|
specific to Chronic Pulmonary Infection |
until 1 year after treatment
|
|
DLQI
Prazo: until 1 year after treatment
|
specific to HS |
until 1 year after treatment
|
|
HiSQoL
Prazo: until 1 year after treatment
|
specific to HS |
until 1 year after treatment
|
|
Systemic and local phage exposure per route of administration
Prazo: until 1 year after treatment
|
Specific to MSI, CRS, Chronic pulmonary infection, HS, bacteremia |
until 1 year after treatment
|
|
Duration of phage activity in blood or locally
Prazo: until 1 year after treatment
|
Phage kinetics / pharmacology |
until 1 year after treatment
|
|
Change in phage-neutralizing activity measured by serum neutralization test
Prazo: until 1 year after treatment
|
Phage-neutralizing activity in serum will be assessed using a serum neutralization test (adapted Adams protocol) by measuring the reduction in viable phage titer after incubation with patient serum compared with baseline. Results will be expressed as the log10 reduction in phage titer. |
until 1 year after treatment
|
|
Change in bacterial load of the targeted pathogen measured by quantitative microbiological culture
Prazo: until 1 year after treatment
|
Change in bacterial load of the targeted bacterial pathogen in clinical samples collected during and after phage therapy, quantified by microbiological culture and expressed as CFU per mL. |
until 1 year after treatment
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Willem-Jan Metsemakers, MD, PhD, UZ / KU Leuven
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças Genéticas, Congênitas
- Infecções
- Doenças Respiratórias
- Doenças do aparelho digestivo
- Doenças pulmonares
- Lactente, Recém Nascido, Doenças
- Doenças brônquicas
- Doenças pancreáticas
- Doenças de pele
- Infecções bacterianas
- Infecções Bacterianas e Micoses
- Doenças das glândulas sudoríparas
- Doenças de pele, bacterianas
- Doenças de Pele Infecciosas
- Supuração
- Hidradenite
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Doenças da Pele e do Tecido Conjuntivo
- Doença
- Hidradenite supurativa
- Fibrose cística
- Bronquiectasia
Outros números de identificação do estudo
Outros números de identificação do estudo
- S64854
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .